Canada · Delayed Price · Currency is CAD PharmaCorp Rx Statistics
Total Valuation
PharmaCorp Rx has a market cap or net worth of CAD 81.82 million. The enterprise value is 62.62 million.
| Market Cap | 81.82M |
| Enterprise Value | 62.62M |
Important Dates
The next estimated earnings date is Wednesday, November 18, 2026.
| Earnings Date | Nov 18, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
PharmaCorp Rx has 174.08 million shares outstanding. The number of shares has increased by 31.90% in one year.
| Current Share Class | 174.08M |
| Shares Outstanding | 174.08M |
| Shares Change (YoY) | +31.90% |
| Shares Change (QoQ) | -0.07% |
| Owned by Insiders (%) | 10.66% |
| Owned by Institutions (%) | 6.23% |
| Float | 155.52M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 28.14 |
| PS Ratio | 2.99 |
| PB Ratio | 1.54 |
| P/TBV Ratio | 3.60 |
| P/FCF Ratio | 1,905.06 |
| P/OCF Ratio | 356.44 |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 2.28 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | 1,458.15 |
Financial Position
The company has a current ratio of 7.36, with a Debt / Equity ratio of 0.08.
| Current Ratio | 7.36 |
| Quick Ratio | 6.53 |
| Debt / Equity | 0.08 |
| Debt / EBITDA | n/a |
| Debt / FCF | 103.09 |
| Interest Coverage | -10.02 |
Financial Efficiency
Return on equity (ROE) is -2.51% and return on invested capital (ROIC) is -3.89%.
| Return on Equity (ROE) | -2.51% |
| Return on Assets (ROA) | -1.65% |
| Return on Invested Capital (ROIC) | -3.89% |
| Return on Capital Employed (ROCE) | -2.17% |
| Weighted Average Cost of Capital (WACC) | -18.06% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | 5 |
| Asset Turnover | 0.55 |
| Inventory Turnover | 6.88 |
Taxes
In the past 12 months, PharmaCorp Rx has paid 279,332 in taxes.
| Income Tax | 279,332 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -2.08% in the last 52 weeks. The beta is -4.26, so PharmaCorp Rx's price volatility has been lower than the market average.
| Beta (5Y) | -4.26 |
| 52-Week Price Change | -2.08% |
| 50-Day Moving Average | 0.50 |
| 200-Day Moving Average | 0.46 |
| Relative Strength Index (RSI) | 39.84 |
| Average Volume (20 Days) | 161,339 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, PharmaCorp Rx had revenue of CAD 27.41 million and -1.07 million in losses. Loss per share was -0.01.
| Revenue | 27.41M |
| Gross Profit | 10.83M |
| Operating Income | -1.31M |
| Pretax Income | -769,486 |
| Net Income | -1.07M |
| EBITDA | -261,541 |
| EBIT | -1.31M |
| Loss Per Share | -0.01 |
Balance Sheet
The company has 24.01 million in cash and 4.43 million in debt, with a net cash position of 19.59 million or 0.11 per share.
| Cash & Cash Equivalents | 24.01M |
| Total Debt | 4.43M |
| Net Cash | 19.59M |
| Net Cash Per Share | 0.11 |
| Equity (Book Value) | 53.17M |
| Book Value Per Share | 0.30 |
| Working Capital | 24.95M |
Cash Flow
In the last 12 months, operating cash flow was 229,546 and capital expenditures -186,598, giving a free cash flow of 42,948.
| Operating Cash Flow | 229,546 |
| Capital Expenditures | -186,598 |
| Depreciation & Amortization | 1.05M |
| Net Borrowing | 2.79M |
| Free Cash Flow | 42,948 |
| FCF Per Share | 0.00 |
Margins
Gross margin is 39.53%, with operating and profit margins of -4.79% and -3.89%.
| Gross Margin | 39.53% |
| Operating Margin | -4.79% |
| Pretax Margin | -2.81% |
| Profit Margin | -3.89% |
| EBITDA Margin | -0.95% |
| EBIT Margin | -4.79% |
| FCF Margin | 0.16% |
Dividends & Yields
PharmaCorp Rx does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -31.90% |
| Shareholder Yield | -31.90% |
| Earnings Yield | -1.30% |
| FCF Yield | 0.05% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Analyst Forecast
The average price target for PharmaCorp Rx is 0.67, which is 42.55% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | 0.67 |
| Price Target Difference | 42.55% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (3Y) | 59.87% |
| EPS Growth Forecast (3Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
PharmaCorp Rx has an Altman Z-Score of 4.52 and a Piotroski F-Score of 5.
| Altman Z-Score | 4.52 |
| Piotroski F-Score | 5 |